Last reviewed · How we verify

chamomile tea

National Center for Complementary and Integrative Health (NCCIH) · FDA-approved active Small molecule

Chamomile tea contains bioactive compounds that bind to benzodiazepine and GABA receptors, promoting relaxation and reducing anxiety through central nervous system modulation.

Chamomile tea contains bioactive compounds that bind to benzodiazepine and GABA receptors, promoting relaxation and reducing anxiety through central nervous system modulation. Used for Anxiety and nervousness, Insomnia and sleep disturbances, Gastrointestinal discomfort and digestive support.

At a glance

Generic namechamomile tea
SponsorNational Center for Complementary and Integrative Health (NCCIH)
Drug classHerbal anxiolytic/sedative
TargetGABA receptors, benzodiazepine receptors
ModalitySmall molecule
Therapeutic areaNeurology, Sleep Medicine, Gastroenterology
PhaseFDA-approved

Mechanism of action

Chamomile contains flavonoids and other phytochemicals, particularly apigenin, which interact with GABAergic and benzodiazepine receptor systems in the brain. These interactions enhance inhibitory neurotransmission, leading to sedative, anxiolytic, and muscle-relaxant effects. Additionally, chamomile may modulate inflammatory pathways and possess antioxidant properties that contribute to its traditional use in promoting sleep and digestive comfort.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: